These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 1850553)

  • 1. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist.
    Yamamura Y; Ogawa H; Chihara T; Kondo K; Onogawa T; Nakamura S; Mori T; Tominaga M; Yabuuchi Y
    Science; 1991 Apr; 252(5005):572-4. PubMed ID: 1850553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of a new V1 antagonist (OPC-21268) on vascular action of vasopressin in cultured rat vascular smooth muscle cells.
    Okada K; Ishikawa S; Saito T
    Biochem Biophys Res Commun; 1991 Jul; 178(2):707-12. PubMed ID: 1650196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of an orally active vasopressin V1 receptor antagonist.
    Burrell LM; Phillips PA; Stephenson J; Risvanis J; Hutchins AM; Johnston CI
    Clin Exp Pharmacol Physiol; 1993 May; 20(5):388-91. PubMed ID: 8391950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a novel orally effective V1-receptor antagonist, OPC-21268, on AVP-induced sympathoinhibition.
    Masaki H; Imaizumi T; Harada S; Momohara M; Hirooka Y; Takeshita A
    Am J Physiol; 1993 Jun; 264(6 Pt 2):R1089-94. PubMed ID: 8391757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat.
    Burrell LM; Phillips PA; Stephenson JM; Risvanis J; Rolls KA; Johnston CI
    Hypertension; 1994 Jun; 23(6 Pt 1):737-43. PubMed ID: 8206571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist.
    Yamamura Y; Ogawa H; Yamashita H; Chihara T; Miyamoto H; Nakamura S; Onogawa T; Yamashita T; Hosokawa T; Mori T
    Br J Pharmacol; 1992 Apr; 105(4):787-91. PubMed ID: 1387020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a novel non-peptide vasopressin V1 receptor antagonist (OPC-21268) in the rat.
    Burrell LM; Phillips PA; Stephenson J; Risvanis J; Hutchins AM; Johnston CI
    J Endocrinol; 1993 Aug; 138(2):259-66. PubMed ID: 8228734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of OPC-21268, an orally effective vasopressin V1 receptor antagonist in humans.
    Imaizumi T; Harada S; Hirooka Y; Masaki H; Momohara M; Takeshita A
    Hypertension; 1992 Jul; 20(1):54-8. PubMed ID: 1319959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human internal mammary artery responses to non-peptide vasopressin antagonists.
    Liu JJ; Phillips PA; Burrell LM; Buxton BB; Johnston CI
    Clin Exp Pharmacol Physiol; 1994 Feb; 21(2):121-4. PubMed ID: 8039263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced pressor response in spontaneously hypertensive rats induced by stimulation of vasopressin-V1 receptors.
    Yamauchi T; Ogura T; Oishi T; Harada K; Hashimoto M; Mimura Y; Asano N; Ota Z; Kageyama J
    Acta Med Okayama; 1995 Feb; 49(1):53-9. PubMed ID: 7762410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasopressin and a nonpeptide antidiuretic hormone receptor antagonist (OPC-31260).
    Burrell LM; Phillips PA; Stephenson JM; Risvanis J; Johnston CI
    Blood Press; 1994 Mar; 3(1-2):137-41. PubMed ID: 8199714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of OPC-21268, an oral, nonpeptide arginine vasopressin V1 receptor antagonist, on a patient with congestive heart failure.
    Miura Y; Yamada K; Nakayama M; Nakano H; Suzuki S; Tsuchida H; Yoshida S
    Clin Nephrol; 1993 Jul; 40(1):60-1. PubMed ID: 8395369
    [No Abstract]   [Full Text] [Related]  

  • 13. Distinct mechanisms of action of V1 antagonists OPC-21268 and [d(CH2)5Tyr(Me)AVP] in mesangial cells.
    Jamil KM; Watanabe T; Nakao A; Okuda T; Kurokawa K
    Biochem Biophys Res Commun; 1993 Jun; 193(2):738-43. PubMed ID: 8390252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent antagonistic action of OPC-31260, a vasopressin V2 receptor antagonist, on [Arg8]vasopressin-induced vasoconstriction in isolated simian femoral arteries.
    Chiba S; Tsukada M
    Eur J Pharmacol; 1992 Oct; 221(2-3):393-5. PubMed ID: 1330628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of vasopressin action in vascular smooth muscle by the V1 antagonist OPC-21268.
    Li X; Kribben A; Wieder ED; Tsai P; Nemenoff RA; Schrier RW
    Hypertension; 1994 Feb; 23(2):217-22. PubMed ID: 8307632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OPC-21268 antagonizes arginine vasopressin-induced vasoconstrictor response in the spinally-anesthetized dog.
    Chihara T; Nakamura S; Onogawa T; Yamashita T; Yamamura Y; Mori T; Tominaga M; Yabuuchi Y
    Jpn J Pharmacol; 1995 Jul; 68(3):345-7. PubMed ID: 7474558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antidiuretic effects of a nonpeptide vasopressin V(2)-receptor agonist, OPC-51803, administered orally to rats.
    Nakamura S; Hirano T; Tsujimae K; Aoyama M; Kondo K; Yamamura Y; Mori T; Tominaga M
    J Pharmacol Exp Ther; 2000 Dec; 295(3):1005-11. PubMed ID: 11082435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blocking effects of V1 (OPC-21268) and V2 (OPC-31260) antagonists on the negative inotropic response to vasopressin in isolated dog heart preparations.
    Furukawa Y; Takayama S; Ren LM; Sawaki S; Inoue Y; Chiba S
    J Pharmacol Exp Ther; 1992 Nov; 263(2):627-31. PubMed ID: 1331408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of AVP.V1-receptor antagonist on urinary albumin excretion and renal hemodynamics in NIDDM nephropathy: role of AVP.V1-receptor.
    Yamada K; Nakano H; Nishimura M; Yoshida S
    J Diabetes Complications; 1995; 9(4):326-9. PubMed ID: 8573758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors.
    Serradeil-Le Gal C; Wagnon J; Garcia C; Lacour C; Guiraudou P; Christophe B; Villanova G; Nisato D; Maffrand JP; Le Fur G
    J Clin Invest; 1993 Jul; 92(1):224-31. PubMed ID: 8392086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.